Alcohol Use Disorder

#Alcohol Use Disorder #Clinical trials #GLP-1 #Semaglutide #Wegovy #Weight loss

Weight-loss pill may quieten alcohol cravings

New research has shown that people taking oral semaglutide – the active ingredient used in Wegovy – experienced fewer heavy-drinking days, consumed fewer drinks when they did drink and reported weaker everyday cravings than those given a placebo. The eight-week randomised clinical trial involved 50 adults with moderate-to-severe alcohol use… Read More

#News

Magic Mushrooms in laboratory. Psilocybin science and research.
#Alcohol Use Disorder #Mental health #Oncology #Psilocybin #Psychedelics #Psychiatry

Findings support positive mental health benefits of psychedelics

One or two doses of psilocybin may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests.   A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder.  In the… Read More

#News

#Alcohol Use Disorder #Breast cancer #Clinical trials #Covid-19 #FDA #Mergers and acquisitions #Psychedelics

This week in drug discovery (25-29 March) 

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders… Read More

#News

Alcohol use disorder
#Alcohol Use Disorder #Beckley Psytech #Phase II trial #Psychedelics

Could a novel psychedelic treat alcohol use disorder?

A novel psychedelic compound, combined with psychological support, will be explored as a potential new treatment for people living with alcohol use disorder (AUD) in a Phase IIa study. The trial uses Beckley Psytech’s lead candidate BPL-003, a short-duration and fast-acting synthetic formulation of psychedelic mebufotenin… Read More

#News

Alcohol use disorder
#Alcohol Use Disorder #Kinnov Therapeutics #Neuroscience #Phase II trial

Drug halves alcohol consumption to aid alcohol dependence

Kinnov Therapeutics’ Phase II study for its lead compound KT-110 has shown that the treatment can halve alcohol consumption amongst heavy drinkers in three months. The trial showed that KT-110 has superior efficacy in significantly reducing alcohol consumption in heavy drinkers by 26 to 30 grams… Read More

#News